Novartis' Galvus NDA Follows Close On The Heels Of Merck's Januvia
This article was originally published in The Pink Sheet Daily
Executive Summary
The likely late November user fee date for Novartis' DPP-IV inhibitor vildagliptin is mere weeks behind that for sitagliptin.